Articles related to Hematology

In this podcast, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens.

The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.

The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.

According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.